On September 26, 2024, in Shanghai —— The final of the 2024 "Maker China" Shanghai SME Innovation and Entrepreneurship Competition was held at the Zhangjiang Science Hall. After fierce competition, Escugen Biotechnology stood out among numerous finalists and won the third prize in the corporate group.
The final was organized by the Shanghai Municipal Commission of Economy and Informatization, the Shanghai Federation of Trade Unions, the Shanghai Women's Federation, and the Zhangjiang Science City Construction and Management Office. A panel of 11 experts from the investment community was invited to form the judging committee. Focusing on the future development trends of industries, the competition was divided into six main tracks: electronic information, digital economy, green and low-carbon, high-end equipment, life and health, and fashion consumption. The aim was to select and nurture a group of innovative enterprises that will lay the foundation for industrial development, and to stimulate the innovation drive of SMEs.
Escugen's participating project, titled "Best-in-Class Trop-2 ADC ESG401 Clinical Research," introduced the company's lead Phase III clinical pipeline, ESG401. Thanks to its outstanding performance in research and clinical trials, the project received high praise from the expert judges and ultimately won the third prize in the corporate group, emerging from fierce competition.
The "Maker China" competition not only provides a high-level platform for companies to showcase their innovative achievements but also offers comprehensive support and services to participating companies through industry-finance integration and project incubation. Escugen's award this time is not only an affirmation of the company's scientific research capabilities by the competition but also a recognition of its innovative achievements in the field of cancer treatment.
About "Maker China"
"Maker China" is a national innovation and entrepreneurship competition co-hosted by the Ministry of Industry and Information Technology and the Ministry of Finance of China. The competition aims to stimulate innovation potential, gather entrepreneurial resources, and create an atmosphere conducive to "mass entrepreneurship and innovation." It is designed to build a platform for SMEs and makers to showcase their achievements, integrate with industry and finance, and incubate projects. Through this platform, the competition is committed to discovering and nurturing a group of excellent projects and teams, giving birth to new products, technologies, models, and business forms. It aims to enhance the professional capabilities of SMEs, promote their transformation and upgrading into specialized, refined, and unique "little giant" enterprises, and facilitate collaborative innovation and development between large and small enterprises. This, in turn, supports the construction of a strong manufacturing and cyber nation. The competition consists of regional contests, thematic contests, and a final, offering SMEs and makers a valuable opportunity to showcase their innovative achievements, obtain financing support, and realize project incubation.
About Escugen Biotechnology
Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC (antibody-drug conjugate) drugs. Currently, Escugen's lead Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC pipeline targeting new or validated targets. Escugen has also successfully licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.
